Phase 2 N=10 Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: The Number of Subjects With Adverse Events — 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Phase 2 N=52 LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Phase 2 N=57 A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Phase 2 N=151 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 2 N=19 CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
Phase 2 N=39 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Overall Survival — 25 Participants
Phase 3 N=205 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Childhood Acute Basophilic Leukemia · Childhood Acute Eosinophilic Leukemia · Childhood Acute Erythroleukemia (M6)
Primary: Event-free Survival (EFS) at 3 Years — 90.1 percentage
Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Phase 2 N=16 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Phase 2 N=50 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts — 38; 33; 41; 23 Participants
Phase 2 N=47 Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Phase 2 N=14 Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=34 Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Complete Remission — 0; 0; 0; 2 participants
Phase 2 N=40 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
AML
Primary: Complete Response Rate — 19 Participants
Phase 3 N=223 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Phase 2 N=50 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants
Phase 2 N=52 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Phase 2 N=25 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia — 7; 4; 0; 9 participants
Phase 2 N=68 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia
Primary: Progression-free Survival — 41.2; 26.9 percentage of patients
Phase 3 N=25 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Acute Myeloid Leukemia/Transient Myeloproliferative Disorder · Adult Acute Myeloid Leukemia in Remission
Primary: Overall Survival — 6; 6 participants
Phase 2 N=10 Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Response — 0; 0; 4; 5 Participants
Phase 2 N=52 Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia
Primary: Most Efficacious and Tolerated Dosage of Decitabine (Period 1) — 0; 0; 0; 1 Incidents
N/A N=12 Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Syndrome · Myeloproliferative Neoplasm
Primary: Overall Survival of Patients Over Age 60 With Newly Diagnosed AML/High Risk MDS — 7 participants
Phase 2 N=24 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants
Phase 2 N=88 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Leukemia
Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants
Phase 2 N=40 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response — 10 Participants